Square 1 Bank and Trinity Capital Investment announced their recent collaboration and closing of a $5 million credit facility to meet the debt financing needs of Sirrus, Inc., an industry leader in monomer and derivatives manufacturing.

Sirrus was searching for a new lender to support further commercialization of their monomer and polymer technologies as well as provide additional working capital to complement their recently raised equity. In February 2015, Sirrus closed their Series B round of equity funding led by major investors Braemar Energy Ventures and General Motors Ventures, bringing the company's total invested capital to more than $35 million.

Formerly known as Bioformix, Sirrus is bringing to the market a new technology platform based on 1,1 dicarbonyl substituted alkenes. This new chemistry has wide applicability in adhesives, sealants, coatings, and resins among other technologies. The company's most well-known products, Chemilian™ and Forza™, were breakthroughs in monomer technology and established Sirrus as a pioneer in the field.

"We are excited to have partnered with both Square 1 Bank and Trinity Capital on this transaction. This capital provides Sirrus with additional runway to achieve our growth plan and better serve our announced and soon to be announced partners that provide chemistry enabled solutions to manufacturers and consumers," said Jeff Uhrig, CEO of Sirrus.  

"Square 1 Bank is excited about the wide application set of the Sirrus technology," added Ryan Dammeyer, managing director of Square 1 Bank's Midwest region. "We are proud to partner with Sirrus Chemistry and Trinity Capital Investment to continue to support the novel technology and pursue its ever growing commercial applications."

Square 1 Bank is a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion.